AJP - Endo AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 278: E134-E139, 2000;
0193-1849/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (38)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tavares, W.
Right arrow Articles by Brubaker, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tavares, W.
Right arrow Articles by Brubaker, P. L.
Vol. 278, Issue 1, E134-E139, January 2000

Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats

Wendy Tavares1, Daniel J. Drucker2,3, and Patricia L. Brubaker1,2

Departments of 1 Physiology and 2 Medicine, University of Toronto, Toronto, Ontario M5S 1A8; and 3 Banting and Best Diabetes Centre, Toronto Hospital, Toronto, Ontario, Canada M5G 2C4

The intestinotropic hormone glucagon-like peptide (GLP)-2-(1---33) is cleaved in vitro to GLP-2-(3---33) by dipeptidyl peptidase IV (DP IV). To determine the importance of DP IV versus renal clearance in the regulation of circulating GLP-2-(1---33) levels in vivo, GLP-2-(1---33) or the DP IV-resistant analog [Gly2]GLP-2 was injected in normal or DP IV-negative rats and assayed by HPLC and RIA. Normal rats showed a steady degradation of GLP-2-(1---33) to GLP-2-(3---33) over time, whereas little or no conversion was detected for GLP-2-(1---33) in DP IV-negative rats and for [Gly2]GLP-2 in normal rats. To determine the role of the kidney in clearance of GLP-2-(1---33) from the circulation, normal rats were bilaterally nephrectomized, and plasma immunoreactive GLP-2 levels were measured. The slope of the disappearance curves for both GLP-2-(1---33) and [Gly2]GLP-2 were significantly reduced in nephrectomized compared with nonnephrectomized rats (P < 0.01). In contrast to both GLP-2-(1---33) and [Gly2]GLP-2, GLP-2-(3---33) did not stimulate intestinal growth in a murine assay in vivo. Thus the intestinotropic actions of GLP-2-(1---33) are determined both by the actions of DP IV and by the kidney in vivo in the rat.

dipeptidyl peptidase IV; kidney; clearance; degradation


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
J.-F. Marier, M. Beliveau, M.-S. Mouksassi, P. Shaw, J. Cyran, J. Kesavan, J. Wallens, H. Zahir, D. Wells, and J. Caminis
Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects
J. Clin. Pharmacol., November 1, 2008; 48(11): 1289 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. C. McDonagh, J. Lee, A. Izzo, and P. L. Brubaker
Role of glial cell-line derived neurotropic factor family receptor {alpha}2 in the actions of the glucagon-like peptides on the murine intestine
Am J Physiol Gastrointest Liver Physiol, August 1, 2007; 293(2): G461 - G468.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Y. Anini, A. Izzo, G. Y. Oudit, P. H. Backx, and P. L. Brubaker
Role of phosphatidylinositol-3 kinase-{gamma} in the actions of glucagon-like peptide-2 on the murine small intestine
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1599 - E1606.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Ferrone and J. S Scolapio
Teduglutide for the Treatment of Short Bowel Syndrome
Ann. Pharmacother., June 1, 2006; 40(6): 1105 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
E. M Sinclair and D. J. Drucker
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Physiology, October 1, 2005; 20(5): 357 - 365.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. L. Estall and D. J. Drucker
Dual Regulation of Cell Proliferation and Survival via Activation of Glucagon-Like Peptide-2 Receptor Signaling
J. Nutr., November 1, 2003; 133(11): 3708 - 3711.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. G. Burrin, Y. Petersen, B. Stoll, and P. Sangild
Glucagon-Like Peptide 2: A Nutrient-Responsive Gut Growth Factor
J. Nutr., March 1, 2001; 131(3): 709 - 712.
[Abstract] [Full Text]

Home page
 J. Nutr.Home page
J. B. van Goudoever, B. Stoll, B. Hartmann, J. J. Holst, P. J. Reeds, and D. G. Burrin
Secretion of Trophic Gut Peptides Is Not Different in Bolus- and Continuously Fed Piglets
J. Nutr., March 1, 2001; 131(3): 729 - 732.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Marguet, L. Baggio, T. Kobayashi, A.-M. Bernard, M. Pierres, P. F. Nielsen, U. Ribel, T. Watanabe, D. J. Drucker, and N. Wagtmann
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
PNAS, June 6, 2000; 97(12): 6874 - 6879.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online